GSK plc (NYSE:GSK) Shares Sold by Greenleaf Trust

Greenleaf Trust reduced its position in GSK plc (NYSE:GSK) by 19.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,269 shares of the pharmaceutical company’s stock after selling 2,020 shares during the quarter. Greenleaf Trust’s holdings in GSK were worth $338,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of GSK. Eastern Bank acquired a new stake in GSK during the 3rd quarter worth $26,000. Sequoia Financial Advisors LLC raised its holdings in shares of GSK by 2.6% in the third quarter. Sequoia Financial Advisors LLC now owns 22,937 shares of the pharmaceutical company’s stock valued at $938,000 after buying an additional 577 shares during the last quarter. Foundations Investment Advisors LLC boosted its stake in shares of GSK by 4.8% during the third quarter. Foundations Investment Advisors LLC now owns 10,122 shares of the pharmaceutical company’s stock worth $414,000 after buying an additional 466 shares during the period. Ledyard National Bank grew its holdings in shares of GSK by 24.1% during the third quarter. Ledyard National Bank now owns 24,281 shares of the pharmaceutical company’s stock worth $993,000 after buying an additional 4,712 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in GSK by 40.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 11,764 shares of the pharmaceutical company’s stock valued at $481,000 after acquiring an additional 3,405 shares during the period. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Trading Down 0.6 %

Shares of GSK stock opened at $37.52 on Friday. GSK plc has a 1-year low of $33.67 and a 1-year high of $45.92. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.82 and a quick ratio of 0.54. The business’s fifty day moving average price is $41.12 and its 200 day moving average price is $41.14. The firm has a market capitalization of $77.76 billion, a PE ratio of 15.13, a P/E/G ratio of 1.23 and a beta of 0.65.

GSK (NYSE:GSK) last posted its quarterly earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. GSK had a net margin of 12.87% and a return on equity of 51.48%. The business had revenue of $9.95 billion for the quarter, compared to analysts’ expectations of $9.49 billion. As a group, sell-side analysts forecast that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, October 10th. Stockholders of record on Friday, August 16th were given a dividend of $0.3843 per share. This represents a $1.54 dividend on an annualized basis and a dividend yield of 4.10%. This is an increase from GSK’s previous quarterly dividend of $0.38. The ex-dividend date was Friday, August 16th. GSK’s dividend payout ratio (DPR) is presently 62.10%.

Insider Transactions at GSK

In other news, major shareholder Plc Gsk acquired 2,791,930 shares of GSK stock in a transaction that occurred on Friday, September 27th. The stock was purchased at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the acquisition, the insider now owns 16,775,691 shares in the company, valued at $134,205,528. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 10.00% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on GSK shares. Argus raised GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Barclays upgraded shares of GSK to a “hold” rating in a research report on Tuesday, August 27th. Jefferies Financial Group upped their price objective on shares of GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a research report on Tuesday, July 2nd. Finally, UBS Group cut shares of GSK from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Four investment analysts have rated the stock with a hold rating, two have issued a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat, GSK currently has a consensus rating of “Buy” and a consensus price target of $50.00.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.